Mult Scler. 2008 Jul;14(6):857-9. Epub 2008 Jun 23.

Interferon beta therapy increases serum ferritin levels in patients with relapsing-remitting multiple sclerosis.

Sena A, Pedrosa R, Ferret-Sena V, Cascais MJ, Roque R, Araújo C, Couderc R.

Source

Departamento de Bioquimica, Faculdade de Ciencias Médicas, Universidade Nova de Lisboa, Lisbon, Portugal. armando.sena@fcm.unl.pt

Abstract

Serum ferritin levels have been found to be increased in patients with active progressive multiple sclerosis (MS). However, its levels are reported to be unchanged in stable and in active relapsing-remitting (RR) form of the disease. No research to date has assessed the influence of interferon beta (IFN-beta) on ferritin concentrations. In this study, serum ferritin levels were measured in 43 individuals with RR-MS and 38 age- and sex-matched control volunteers. There were no significant differences between controls and patients under stable and untreated conditions. In patients at 12 months after the beginning of IFN-beta therapy, ferritin levels were higher in women and in men, in comparison with baseline (71.4 +/- 58.6 vs 43.4 +/- 29.9 ng/mL, P = 0.0006 and 216.0 +/- 124.3 vs 127.8 +/- 74.9 ng/mL, P = 0.0022, respectively). These results suggest that larger prospective studies are required to evaluate the role of serum ferritin in MS and its potential usefulness in monitoring responses to immunomodulatory therapies.

PMID:: 18573825; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Supplemental Content

Save items

Related citations in PubMed

Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy. [J Neuroimmunol. 2004]
Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
Fainardi E, Rizzo R, Melchiorri L, Castellazzi M, Govoni V, Caniatti L, Paolino E, Tola MR, Granieri E, Baricordi OR. J Neuroimmunol. 2004 Mar; 148(1-2):206-11.
Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability. [Mult Scler. 2001]
Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability.
Flachenecker P, Reiners K, Krauser M, Wolf A, Toyka KV. Mult Scler. 2001 Oct; 7(5):327-34.
Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. [Clin Neurol Neurosurg. 2006]
Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
Boz C, Ozmenoglu M, Velioglu S, Kilinc K, Orem A, Alioglu Z, Altunayoglu V. Clin Neurol Neurosurg. 2006 Feb; 108(2):124-8.
Review [Subcutaneous interferon-beta-1a in the treatment of multiple sclerosis]. [Wien Med Wochenschr. 2008]
Review [Subcutaneous interferon-beta-1a in the treatment of multiple sclerosis].
Fertl E, Krichmayr M. Wien Med Wochenschr. 2008; 158(3-4):98-109.
Review Treatment of multiple sclerosis with human beta interferon. [Int MS J. 2005]
Review Treatment of multiple sclerosis with human beta interferon.
Goodin DS. Int MS J. 2005 Nov; 12(3):96-108.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Recent activity

Clear Turn Off Turn On

Interferon beta therapy increases serum ferritin levels in patients with relapsi...
Interferon beta therapy increases serum ferritin levels in patients with relapsing-remitting multiple sclerosis.
Mult Scler. 2008 Jul ;14(6):857-9. Epub 2008 Jun 23 .

PubMed
A structured approach for the engineering of biochemical network models, illustr...
A structured approach for the engineering of biochemical network models, illustrated for signalling pathways.
Brief Bioinform. 2008 Sep ;9(5):404-21. Epub 2008 Jun 23 .

PubMed
Characterization of Melan-A reactive memory CD8+ T cells in a healthy donor.
Characterization of Melan-A reactive memory CD8+ T cells in a healthy donor.
Int Immunol. 2008 Aug ;20(8):1087-96. Epub 2008 Jun 23 .

PubMed
Estimating mean sojourn time and screening sensitivity using questionnaire data ...
Estimating mean sojourn time and screening sensitivity using questionnaire data on time since previous screening.
J Med Screen. 2008 ;15(2):83-90.

PubMed
Changing expression of the genes related to human hair graying.
Changing expression of the genes related to human hair graying.
Eur J Dermatol. 2008 Jul-Aug ;18(4):397-9. Epub 2008 Jun 23 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Interferon beta therapy increases serum ferritin levels in patients with relapsing-remitting multiple sclerosis.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Supplemental Content

Save items

Related citations in PubMed

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information